AMGEN 20120139: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Indication :

Tous les types de tumeurs


Sponsor :

AMGEN


Phase :

registre


Ligne :

N/A


Traitement :

Observational registry program


Spécificités :

Study Population: Subjects who have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial.


Site :

CHUV


Contact(s) :
Olivier Michielin
Investigateur principal

CHUV
Oncologie

Rue du Bugnon 46
Lausanne
1011

+41 (0)21 314 01 85
olivier.michielin@chuv.ch

Primary objective :

• To evaluate the long-term safety of talimogene laherparepvec
• To monitor subject overall survival
• To monitor use of subsequent anti-cancer therapy, for the tumor indication in the prior Amgen or BioVEX-sponsored clinical trial, including retreatment with marketed talimogene laherparepvec in subjects previously enrolled in Amgen or BioVEX-sponsored clinical trials


Inclusion criteria :
  1. Ages Eligible for Study: 18 Years to 99 Years (Adult, Senior)
  2. Sexes Eligible for Study: All
  3. All subjects must provide informed consent prior to initiation of any study activities.
  4. All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial and must have permanently discontinued treatment on that trial.

Exclusion criteria :
  1. Subjects currently receiving or planning to receive talimogene laherparepvec in the next 30 days.